

C6 vs Pathway Expression

The heatmap displays the correlation between C6 expression and various pathways. The color scale ranges from red (negative correlation) to blue (positive correlation). The y-axis lists various pathways and gene sets, and the x-axis represents individual samples. A color bar at the top indicates the C6 expression level for each sample.

Pathway	IC(Δ)	P-val	FDR
C6	-0.694(0.014)	2.62e-06	5.29e-05
BRAF	-0.661(0.008)	2.62e-06	5.29e-05
ETV1_UP	-0.644(0.014)	2.62e-06	5.29e-05
PIGMENT_BIOSYNTHETIC_PROCESS	-0.644(0.010)	2.62e-06	5.29e-05
PIGMENT_METABOLIC_PROCESS	-0.642(0.012)	2.62e-06	5.29e-05
ASTON_MAJOR_DEPRESSIVE_DISORDER_DN	-0.641(0.011)	2.62e-06	5.29e-05
MATTIOLI_MULTIPLE_MYELOMA_SUBGROUPS	-0.635(0.011)	2.62e-06	5.29e-05
P53_DN.V1_DN	-0.617(0.011)	2.62e-06	5.29e-05
LEIN_OLIGODENDROCYTE_MARKERS	-0.615(0.008)	2.62e-06	5.29e-05
MCGOWAN_RSP6_TARGETS_UP	-0.614(0.010)	2.62e-06	5.29e-05
KASLER_HDAC7_TARGETS_1_UP	-0.614(0.010)	2.62e-06	5.29e-05
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM	-0.613(0.008)	2.62e-06	5.29e-05
SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_UP	-0.612(0.011)	2.62e-06	5.29e-05
COPPER_ION_BINDING	-0.611(0.010)	2.62e-06	5.29e-05
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_UP	-0.611(0.010)	2.62e-06	5.29e-05
KIM_MYC_AMPLIFICATION_TARGETS	-0.610(0.012)	2.62e-06	5.29e-05
ONKEN_UVEAL_MELANOMA_DN	-0.601(0.010)	2.62e-06	5.29e-05
MCGOWAN_RSP6_TARGETS	-0.601(0.010)	2.62e-06	5.29e-05
BRAF_UP	-0.600(0.012)	2.62e-06	5.29e-05
NIELSEN_SCHWANNOMA_UP	-0.598(0.012)	2.62e-06	5.29e-05
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_UP	0.632(0.016)	2.62e-06	3.97e-05
BOYVAULT_LIVER_CANCER_SUBCLASS_G1	0.644(0.013)	2.62e-06	3.97e-05
TAUBE_EMT_DN	0.646(0.012)	2.62e-06	3.97e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	0.647(0.014)	2.62e-06	3.97e-05
BRAF_DN	0.647(0.015)	2.62e-06	3.97e-05
FONTAINE_FOLLICULAR_THYROID_ADENOMA_UP	0.649(0.010)	2.62e-06	3.97e-05
GROGER_EMT_DN	0.652(0.012)	2.62e-06	3.97e-05
KEGG_TIGHT_JUNCTION	0.653(0.015)	2.62e-06	3.97e-05
KIM_RESPONSE_TO_TSA_AND_DECITABINE	0.669(0.014)	2.62e-06	3.97e-05
COLDREN_GEFITINIB_RESISTANCE_DN	0.671(0.013)	2.62e-06	3.97e-05
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN	0.672(0.013)	2.62e-06	3.97e-05
MOROSSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_DN	0.680(0.015)	2.62e-06	3.97e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	0.682(0.015)	2.62e-06	3.97e-05
MEISSNER_BRAIN_HCP_WITH_H3K4ME2	0.683(0.014)	2.62e-06	3.97e-05
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION	0.685(0.012)	2.62e-06	3.97e-05
SMID_BREAST_CANCER_NORMAL_LIKE_DN	0.686(0.014)	2.62e-06	3.97e-05
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN	0.693(0.012)	2.62e-06	3.97e-05
REACTOME_TIGHT_JUNCTION_INTERACTIONS	0.695(0.014)	2.62e-06	3.97e-05
VISALA_AGING_LYMPHOCYTE	0.698(0.015)	2.62e-06	3.97e-05
AIGNER_ZEB1_TARGETS	0.716(0.011)	2.62e-06	3.97e-05
P53_DN.V1			